US2021040049A1PendingUtilityA1
Anti-hcmv compositions and methods
Est. expiryNov 10, 2034(~8.3 yrs left)· nominal 20-yr term from priority
Y02A50/30C07D 241/44A61K 31/4035C07D 209/04C07D 215/40C07C 235/38C07C 217/62A61K 31/522A61K 31/47A61P 31/12C07D 209/08A61P 31/20
54
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
This document relates to compounds useful as agents for preventing or treating human cytomegalovirus (HCMV) infections.
Claims
exact text as granted — not AI-modified1 . A composition comprising a compound of Formula I:
wherein:
X is NH or O, provided that when m is 1, X is NH;
R 1 and R 2 are independently selected from H, halo, lower straight chain or branched alkyl, and OR 6 ;
R 3 , R 4 , and R 5 are independently selected from H, halo, —CN, lower straight chain or branched alkyl, and OR 6 ;
each R 6 is independently selected from H, lower straight chain or branched alkyl;
m is 0 or 1;
n is 0, 1, 2 or 3, provided that when m is 1, n is not 3; and
Ar is
substituted with 0, 1 or 2 groups independently selected from halo, —CN, lower straight chain or branched alkyl and wherein:
R 9 is selected from H, lower straight chain or branched alkyl, —C(O)R 10 or —SO 2 R 10 and R 10 is selected from lower straight chain or branched alkyl
or a pharmaceutically acceptable salt thereof.
2 . The composition of claim 1 , wherein Ar is selected from the group consisting of:
wherein:
R 8 is selected from H, halo and —CN;
R 9 is selected from H, lower straight chain or branched alkyl, —C(O)R 10 or —SO 2 R 10 and R 10 is selected from lower straight chain or branched alkyl.
3 . The composition of claim 2 , wherein at least one of R 3 , R 4 , or R 5 is in the ortho position and selected from the group consisting of halo, —CN, a straight chain or branched alkyl of 1 to 4 carbon atoms, and a straight or branched alkoxy of 1 to 4 carbon atoms.
4 . The composition of claim 2 , wherein at least two of R 3 , R 4 , or R 5 is in the ortho position and selected from the group consisting of halo, —CN, a straight chain or branched alkyl of 1 to 4 carbon atoms, and a straight or branched alkoxy of 1 to 4 carbon atoms.
5 . The composition of claim 2 , wherein R 2 is selected from halo, lower straight chain or branched alkyl, and OR 6 .
6 . The composition of claim 2 , wherein the compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
7 . A pharmaceutical composition comprising a compound of Formula I:
wherein:
X is NH or O, provided that when m is 1, X is NH;
R 1 and R 2 are independently selected from H, halo, lower straight chain or branched alkyl, and OR 6 ;
R 3 , R 4 , and R 5 are independently selected from H, halo, —CN, lower straight chain or branched alkyl, and OR 6 ;
each R 6 is independently selected from H, lower straight chain or branched alkyl;
m is 0 or 1;
n is 0, 1, 2 or 3, provided that when m is 1, n is not 3; and
Ar is
substituted with 0, 1 or 2 groups independently selected from halo, —CN, lower straight chain or branched alkyl and wherein:
R 9 is selected from H, lower straight chain or branched alkyl, —C(O)R 10 or —SO 2 R 10 and R 10 is selected from lower straight chain or branched alkyl,
or a pharmaceutically acceptable salt thereof, and
a pharmaceutically acceptable carrier.
8 . The pharmaceutical composition of claim 7 , wherein Ar is selected from the group consisting of:
wherein:
R 8 is selected from H, halo and —CN;
R 9 is selected from H, lower straight chain or branched alkyl, —C(O)R 10 or —SO 2 R 10 and R 10 is selected from lower straight chain or branched alkyl.
9 . The pharmaceutical composition of claim 8 , wherein at least one of R 3 , R 4 , or R 5 is in the ortho position and selected from the group consisting of halo, —CN, a straight chain or branched alkyl of 1 to 4 carbon atoms, and a straight or branched alkoxy of 1 to 4 carbon atoms.
10 . The pharmaceutical composition of claim 8 , wherein at least two of R 3 , R 4 , or R 5 is in the ortho position and selected from the group consisting of halo, —CN, a straight chain or branched alkyl of 1 to 4 carbon atoms, and a straight or branched alkoxy of 1 to 4 carbon atoms.
11 . The pharmaceutical composition of claim 8 , wherein R 2 is selected from halo, lower straight chain or branched alkyl, and OR 6 .
12 . The pharmaceutical composition of claim 8 , wherein the compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
13 . A method for treating or preventing an HCMV infection in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula I:
wherein:
X is NH or O, provided that when m is 1, X is NH;
R 1 and R 2 are independently selected from H, halo, lower straight chain or branched alkyl, and OR 6 ;
R 3 , R 4 , and R 5 are independently selected from H, halo, —CN, lower straight chain or branched alkyl, and OR 6 ;
each R 6 is independently selected from H, lower straight chain or branched alkyl;
m is 0 or 1;
n is 0, 1, 2 or 3, provided that when m is 1, n is not 3; and
Ar is a bicyclic aryl group having between 8 and 12 ring atoms, wherein 0, 1 or 2 ring atoms are heteroatoms independently selected from N, O, S and the bicyclic aryl group is substituted with 0, 1 or 2 groups independently selected from halo, —CN, lower straight chain or branched alkyl;
or a pharmaceutically acceptable salt form thereof, with the proviso that the compound is not
or a pharmaceutically acceptable salt thereof.
14 . The method of claim 13 , wherein Ar is selected from the group consisting of:
wherein:
R 8 is selected from H, halo and —CN;
R 9 is selected from H, lower straight chain or branched alkyl, —C(O)R 10 or —SO 2 R 10 and R 10 is selected from H, lower straight chain or branched alkyl.
15 . The method of claim 14 , wherein at least one of R 3 , R 4 , or R 5 is in the ortho position and selected from the group consisting of halo, —CN, a straight chain or branched alkyl of 1 to 4 carbon atoms, and a straight or branched alkoxy of 1 to 4 carbon atoms.
16 . The method of claim 14 , wherein at least two of R 3 , R 4 , or R 5 is in the ortho position and selected from the group consisting of halo, —CN, a straight chain or branched alkyl of 1 to 4 carbon atoms, and a straight or branched alkoxy of 1 to 4 carbon atoms.
17 . The method of claim 13 , wherein R 2 is selected from halo, lower straight chain or branched alkyl, and OR 6 .
18 . The method of claim 14 , wherein the compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
19 . A method of inhibiting HCMV production comprising contacting an HCMV-infected cell with a therapeutically effective amount of a compound of Formula I:
wherein:
X is NH or O, provided that when m is 1, X is NH;
R 1 and R 2 are independently selected from H, halo, lower straight chain or branched alkyl, and OR 6 ;
R 3 , R 4 , and R 5 are independently selected from H, halo, —CN, lower straight chain or branched alkyl, and OR 6 ;
each R 6 is independently selected from H, lower straight chain or branched alkyl;
m is 0 or 1;
n is 0, 1, 2 or 3, provided that when m is 1, n is not 3; and
Ar is a bicyclic aryl group having between 8 and 12 ring atoms, wherein 0, 1 or 2 ring atoms are heteroatoms independently selected from N, O, S and the bicyclic aryl group is substituted with 0, 1 or 2 groups independently selected from halo, —CN, lower straight chain or branched alkyl;
or a pharmaceutically acceptable salt form thereof, with the proviso that the compound is not
or a pharmaceutically acceptable salt thereof.
20 . The method of claim 19 , wherein Ar is selected from the group consisting of:
wherein:
R 8 is selected from H, halo and —CN;
R 9 is selected from H, lower straight chain or branched alkyl, —C(O)R 10 or —SO 2 R 10 and R 10 is selected from lower straight chain or branched alkyl.
21 . (canceled)
22 . (canceled)
23 . (canceled)
24 . The method of claim 20 , wherein the compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
25 . (canceled)
26 . (canceled)
27 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.